A regulatory and clinical reality check for hospital leaders, quality teams, and the device industry that serves them. About one in four people in a U.S. hospital bed has diabetes or hyperglycemia.¹ Almost none of the continuous glucose monitors used to manage them in 2026 is actually FDA-cleared for that setting.² The COVID-era enforcement discretion that briefly made hospital CGM use legitimate expired on November 7, 2023.³ Two and a half years later, the devices are still